Child in overalls and green t-shirt, smiling at camera

New preliminary research by PHI's Child Health and Development Studies and colleagues finds that grandfathers' smoking and alcohol intake could be linked to an increased risk of autism in their grandchildren.

3 generations of families included in CHDS research

PHI’s Child Health and Development Studies (CHDS), in collaboration with the California Department of Public Health Environmental Health Investigations Branch and the Department of Developmental Services, examined the role that grandparents’ smoking or alcohol consumption might have on their grandchildren’s risk of autism. A previous study found that the maternal grandmothers’ smoking during pregnancy was correlated with an increased risk of autism, but no prior studies have reviewed connections between grandpaternal smoking or alcohol intake and autism.

The study’s preliminary findings suggest a role of perinatal grandparental smoking and drinking in the risk of autism in grandchildren.

Results were presented in an abstract at the International Society for Autism Research Conference in 2020. The CHDS researchers noted that larger epidemiologic studies with information on the grandparent and parent generations and animal studies are needed to confirm these findings and investigate biological mechanisms, including possible epigenetic alterations to the germ line.

Work With Us

You change the world. We do the rest. Explore fiscal sponsorship at PHI.

Bring Your Work to PHI

Support Us

Together, we can accelerate our response to public health’s most critical issues.


Find Employment

Begin your career at the Public Health Institute.

See Jobs


Breakthrough Infection Study of Over 600,000 Veterans Shows Declining COVID-19 Vaccine Protection

A new pre-print study of over 600,000 veterans by researchers from PHI and the Veterans Affairs Medical Center finds that overall COVID-19 vaccine protection declined significantly between February and August 2021. Declines were greatest for the Johnson & Johnson vaccine (from 88% in March to 3% in August), followed by PfizerBioNTech (91% to 50%) and Moderna (92% to 64%).


Continue to